Positive Results in SHARP Trial for Merck & Co. (MRK)

Deutsche Bank has published a company alert today on Merck & Co. following results of the SHARP trial. In a note to clients, Deutsche Bank writes, "The SHARP trial compared vascular/atherosclerotic outcomes with Vytorin 10/20 therapy to placebo in 9,400 chronic kidney disease patients (approx. 1/3 on dialysis) with 5 years of followup. Results were positive overall, and no major safety concerns emerged, suggesting that MRK will be able to gain approval for the supplemental indication." Deutsche Bank maintains its Buy rating on MRK which closed Friday at $35.33.